Page 14 - Read Online

Gene signatures in the management of hepatocellular Kuroki H, Imai K, Nitta H, Saito S, Hashimoto D,
carcinoma. Semin Oncol 2012;39:473-85. Chikamoto A, Ishiko T, Watanabe M, Nagano O, Beppu T,
31. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Saya H, Baba H. CD44s signals the acquisition of the
Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, mesenchymal phenotype required for anchorage-independent
Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, cell survival in hepatocellular carcinoma. Br J Cancer
Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation 2014;110:958-66.
in two molecular classes of hepatocellular carcinoma and 44. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S,
experimental modulation by sorafenib. Clin Cancer Res Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O,
2012;18:4997-5007. Saya H, Baba H. CD44s regulates the TGF-beta-mediated
32. Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, mesenchymal phenotype and is associated with poor prognosis
Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS. in patients with hepatocellular carcinoma. Cancer Res
Sequential transcriptome analysis of human liver cancer 2012;72:3414-23.
indicates late stage acquisition of malignant traits. J Hepatol 45. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A,
2014;60:346-53. Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP,
33. Cozzolino AM, Alonzi T, Santangelo L, Mancone C, Conti B, Roughton M, Bridgewater J, Investigators ABCT. Cisplatin
Steindler C, Musone M, Cicchini C, Tripodi M, Marchetti A. plus gemcitabine versus gemcitabine for biliary tract cancer.
TGFbeta overrides HNF4alpha tumor suppressing activity N Engl J Med 2010;362:1273-81.
through GSK3beta inactivation: implication for hepatocellular 46. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M,
carcinoma gene therapy. J Hepatol 2013;58:65-72. Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX,
34. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY,
Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Thorgeirsson SS, Wang XW. Transcriptomic profi ling reveals
Mikulits W. Axl activates autocrine transforming growth hepatic stem-like gene signatures and interplay of miR-200c
factor-beta signaling in hepatocellular carcinoma. Hepatology and epithelial-mesenchymal transition in intrahepatic
2015;61:930-41. cholangiocarcinoma. Hepatology 2012;56:1792-803.
35. Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY, 47. Mizuguchi Y, Isse K, Specht S, Lunz JG 3rd, Corbitt N,
Chen MF. Expression profi le of microRNA-200 family in Takizawa T, Demetris AJ. Small proline rich protein
hepatocellular carcinoma with bile duct tumor thrombus. Ann 2a in benign and malignant liver disease. Hepatology
Surg 2014;259:346-54. 2014;59:1130-43.
36. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced 48. Malka D, Cervera P, Foulon S, Trarbach T,
epithelial-mesenchymal transition targets PTEN and SMAD7 de la Fouchardiere C, Boucher E, Fartoux L, Faivre S,
to promote drug resistance and recurrence of liver cancer. Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T,
Hepatology 2013;58:629-41. Grenier J, Hammel P, Dollinger M, Andre T, Hahn P,
37. Chang RM, Yang H, Fang F, Xu JF, Yang LY. Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D,
MicroRNA-331-3p promotes proliferation and metastasis Rosmorduc O, Greten TF, investigators B. Gemcitabine and
of hepatocellular carcinoma by targeting PH domain oxaliplatin with or without cetuximab in advanced biliary-tract
and leucine-rich repeat protein phosphatase. Hepatology cancer (BINGO): a randomised, open-label, non-comparative
2014;60:1251-63. phase 2 trial. Lancet Oncol 2014;15:819-28.
38. Zhang Y, Li T, Guo P, Kang J, Wei Q, Jia X, Zhao W, 49. Claperon A, Mergey M, Nguyen Ho-Bouldoires TH,
Huai W, Qiu Y, Sun L, Han L. MiR-424-5p reversed Vignjevic D, Wendum D, Chretien Y, Merabtene F, Frazao A,
epithelial-mesenchymal transition of anchorage-independent Paradis V, Housset C, Guedj N, Fouassier L. EGF/EGFR
HCC cells by directly targeting ICAT and suppressed HCC axis contributes to the progression of cholangiocarcinoma
progression. Sci Rep 2014;4:6248. through the induction of an epithelial-mesenchymal transition.
39. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, J Hepatol 2014;61:325-32.
Shen B, Peng C, Li H, Zhan Q, Zhu Z. Upregulation of long 50. Lee MJ, Yu GR, Yoo HJ, Kim JH, Yoon BI, Choi YK,
noncoding RNA ZEB1-AS1 promotes tumor metastasis and Kim DG. ANXA8 down-regulation by EGF-FOXO4
predicts poor prognosis in hepatocellular carcinoma. Oncogene signaling is involved in cell scattering and tumor metastasis
2015; doi: 10.1038/onc.2015.223. of cholangiocarcinoma. Gastroenterology 2009;137:1138-50,
40. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, 50.e1-9.
Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, 51. El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP,
Yang N, Zhou WP, Yang GS, Sun SH. A long noncoding Malek NP, Wilkens L, Plentz RR. Inhibition of hedgehog
RNA activated by TGF-beta promotes the invasion-metastasis signaling attenuates carcinogenesis in vitro and increases
cascade in hepatocellular carcinoma. Cancer Cell necrosis of cholangiocellular carcinoma. Hepatology
2014;25:666-81. 2013;57:1035-45.
41. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, Zhou Z, 52. Meng F, Han Y, Staloch D, Francis T, Stokes A, Francis H.
Chen K, Huang A, Li S, Tang N. Hepatitis C virus core The H4 histamine receptor agonist, clobenpropit, suppresses
protein epigenetically silences SFRP1 and enhances HCC human cholangiocarcinoma progression by disruption of
aggressiveness by inducing epithelial-mesenchymal transition. epithelial mesenchymal transition and tumor metastasis.
Oncogene 2014;33:2826-35. Hepatology 2011;54:1718-28.
42. Benzoubir N, Lejamtel C, Battaglia S, Testoni B, Benassi B, 53. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ,
Gondeau C, Perrin-Cocon L, Desterke C, Thiers V, Samuel D, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A,
Levrero M, Brechot C, Bourgeade MF. HCV core-mediated Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M,
activation of latent TGF-beta via thrombospondin drives the Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR,
crosstalk between hepatocytes and stromal environment. Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M,
J Hepatol 2013;59:1160-8. Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE,
43. Okabe H, Ishimoto T, Mima K, Nakagawa S, Hayashi H, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G,

188 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦